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Introduction: Although there is a considerable amount of data in the literature on safe discontinuation of first-generation
tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia, little is known about discontinuation of
second-generation tyrosine kinase inhibitor therapy. Most previous studies have been focused on dasatinib, and
the few cases of nilotinib withdrawal that have been reported had a median follow-up of 12 months. To the
best of our knowledge, the present report is the first to describe nilotinib withdrawal with 30 months of follow-up.
Case presentation: We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid
leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to
nilotinib. Two years later, he decided to stop nilotinib. Undetectable molecular response persisted for 30 months after
discontinuation of the drug.
Conclusion: Our present case suggests that nilotinib withdrawal is safe for patients with chronic myeloid
leukemia who achieve a stable undetectable molecular response. Our patient was homozygous for killer
immunoglobulin-like receptor haplotype A, previously reported to be a promising immunogenetic marker for
undetectable molecular response. We recommend additional studies to investigate patient immunogenetic profiles
and their potential role in complete response to therapy.
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discontinuationIntroduction
One of the most highly debated challenges physicians face
when treating patients with chronic myeloid leukemia
(CML) is to decide whether tyrosine kinase inhibitor (TKI)
therapy can be stopped or must be continued indefinitely.
The recent European LeukemiaNet (ELN) guidelines for
the management of CML recommend that patients who
respond optimally to TKI treatment be continued on it in-
definitely at the standard suggested dose [1].
Researchers in several studies have reported safe dis-
continuation of first-generation TKI imatinib. Overall,
these studies show a probability of stable undetectable
molecular response (MR) of approximately 40% at 24
months. Factors associated with sustained response are
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ation of undetectable MR [2-4].
However, little is known to date about discontinuation
of second-generation TKI therapy. In one study of 34
patients with CML, the investigators reported the feasi-
bility of discontinuing both nilotinib and dasatinib with
a median follow-up of 12 months [5]. In a recent prelim-
inary report, researchers described safe withdrawal of
dasatinib with a median follow-up of 6 months in 27 pa-
tients previously treated with imatinib [6]. Additionally,
in three case reports of a total of six patients with me-
dian follow-up ranging from 12 to 27 months, the au-
thors showed safe discontinuation in three of the five
patients treated with dasatinib and in one patient treated
with nilotinib [7-9]. Our report concerns an imatinib-
intolerant patient who achieved undetectable MR with
nilotinib. The patient was in undetectable MR4.5 at 30
months after stopping the drug and remains so at the
time of this report.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Our patient was a 64-year-old Caucasian man diagnosed
with chronic phase CML in April 2005. Peripheral blood
tests showed hemoglobin of 13.5g/dl, white blood cell
count of 17.6×109/L and platelet count of 402×109/L.
No organomegaly was observed. Cytogenetic analysis of
the bone marrow aspirate revealed a 46,XY,t(9;22)(q34;
q11.2) karyotype in 100% of metaphases. By qualitative
PCR, we detected the sole presence of the b3a2 tran-
script. According to the patient’s Sokal and Hasford
scores, he was classified as being in an intermediate risk
class. He was started on imatinib 400mg/day. After 6
months, he had achieved a complete cytogenetic re-
sponse and MR3 (BCR-ABL1≤0.01%). Four years later,
the patient became intolerant to imatinib (grade 3 diar-
rhea, probably due to the irritant effect of this drug on
intestinal mucosa) and was switched to nilotinib. Al-
though the recommended dose for patients resistant or
intolerant to imatinib is 800mg/day, our patient was
given 600mg/day because of residual diarrhea.
He achieved early MR4.5 (BCR-ABL1≤0.0032%) and
subsequently undetectable MR4.5, confirmed by nested
RT-PCR (kits from Nanogen Advanced Diagnostics,
Turin, Italy). The patient decided to stop nilotinib after
24 months of treatment. Undetectable MR4.5 persisted
at 30 months after discontinuation of nilotinib and re-
mains so at the time of this report (Figure 1). Investi-
gation of the immune genetic profile of our patient
revealed homozygosity for the killer immunoglobulin-
like receptor (KIR) haplotype A with the following
genes: KIR2DS4, KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1,
KIR3DL2 and KIR3DL3.Figure 1 Clinical course of the patient. BCR-ABL levels measured duringDiscussion
Although the ELN 2013 guidelines do not recommend
discontinuation of TKI therapy in optimal responders,
several attempts have been made to identify patients
who can safely stop treatment [1]. The Italian consensus
is that TKI discontinuation should be considered only
within the context of controlled clinical trials and should
be restricted to patients with MR4.5 sustained for at
least 2 years. The drug needs to be promptly restarted in
patients who lose MR3 [10].
In recent years, more precise definitions of inter-
national scale (IS) deep MR have been introduced: MR4
(BCR-ABL1≤0.01%), MR4.5 (BCR-ABL1≤0.0032%) and
MR5 (BCR-ABL1≤0.001%). An, assay is considered nega-
tive when no BCR-ABL copies are detectable using the
IS with a sensitivity ≥4.5 logs below the standardized
baseline. Indeed, the term complete molecular response
is increasingly being replaced with undetectable molecu-
lar response [1].
Rea et al., in their study of 34 patients with CML, re-
ported a 58% probability of maintaining a stable, deep
MR at 12 months [5]. Most of their patients had previ-
ously been treated with imatinib; patients receiving
second-generation TKI treatment because of intolerance
to imatinib had a significantly higher probability of
achieving stable undetectable MR (67%) compared to
those switched to second-generation TKI because of
suboptimal response or resistance (33%).
Preliminary data on 27 participants enrolled in a larger
study of 63 patients with CML who stopped dasatinib after
achieving undetectable MR for at least 1 year had a mo-
lecular relapse-free survival rate of 44%. Reintroduction ofand after discontinuation of imatinib and nilotinib therapy.
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and none of them progressed to advanced phase CML [6].
However, except for the study by Rea and colleagues [5]
and one anecdotal case report [9], both with a median
follow-up of only 1 year, there is a paucity of data on with-
drawal of nilotinib in patients with CML. Interestingly, our
patient was homozygous for KIR haplotype A, previously
reported by our research team to be a promising immuno-
genetic marker for undetectable MR [11]. The authors of
another recent report suggest a potential role for natural
killer cells in achieving undetectable MR after discontinu-
ation of imatinib [12].
Conclusions
Our present report, to the best of our knowledge, is the
first to describe nilotinib withdrawal with a follow-up of
30 months. Our patient was treated with imatinib for 4
years and achieved MR3 before he was started on re-
placement therapy with nilotinib because of intolerance.
He rapidly achieved undetectable MR and, after 24
months of treatment, decided to stop the drug. He con-
tinued to have undetectable MR for 30 months after
stopping the drug and remains so at the time of this re-
port. Additional studies are recommended to confirm the
feasibility and safety of discontinuing second-generation
TKI therapy.
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